| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcus aureus | 63 | 2024 | 1429 | 10.500 |
Why?
|
| Quinolones | 35 | 2021 | 389 | 6.640 |
Why?
|
| Bacterial Proteins | 61 | 2024 | 3833 | 6.360 |
Why?
|
| Drug Resistance, Bacterial | 48 | 2021 | 1065 | 5.020 |
Why?
|
| Ciprofloxacin | 33 | 2021 | 314 | 4.990 |
Why?
|
| Anti-Infective Agents | 60 | 2023 | 987 | 4.820 |
Why?
|
| Anti-Bacterial Agents | 88 | 2024 | 7475 | 4.740 |
Why?
|
| Staphylococcal Infections | 30 | 2024 | 1396 | 4.650 |
Why?
|
| DNA Gyrase | 22 | 2021 | 86 | 4.520 |
Why?
|
| Escherichia coli Proteins | 17 | 2022 | 1055 | 4.070 |
Why?
|
| Microbial Sensitivity Tests | 62 | 2024 | 1972 | 4.020 |
Why?
|
| Fluoroquinolones | 33 | 2016 | 307 | 3.930 |
Why?
|
| Plasmids | 36 | 2022 | 2268 | 3.920 |
Why?
|
| Membrane Transport Proteins | 15 | 2024 | 1029 | 3.790 |
Why?
|
| Escherichia coli | 50 | 2024 | 4211 | 3.470 |
Why?
|
| Gene Expression Regulation, Bacterial | 24 | 2024 | 1137 | 3.460 |
Why?
|
| DNA Topoisomerase IV | 20 | 2021 | 42 | 2.840 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 19 | 2024 | 592 | 2.790 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 14 | 2017 | 705 | 2.320 |
Why?
|
| Cross Infection | 18 | 2020 | 1427 | 1.920 |
Why?
|
| Enterobacteriaceae | 9 | 2017 | 161 | 1.580 |
Why?
|
| DNA Topoisomerases, Type II | 19 | 2005 | 121 | 1.550 |
Why?
|
| beta-Lactams | 5 | 2024 | 158 | 1.420 |
Why?
|
| Abscess | 9 | 2018 | 606 | 1.420 |
Why?
|
| Tetracycline | 6 | 2024 | 216 | 1.380 |
Why?
|
| Klebsiella pneumoniae | 8 | 2024 | 253 | 1.380 |
Why?
|
| Drug Resistance, Microbial | 30 | 2020 | 832 | 1.370 |
Why?
|
| Serratia marcescens | 4 | 2024 | 48 | 1.330 |
Why?
|
| Topoisomerase II Inhibitors | 16 | 2015 | 94 | 1.320 |
Why?
|
| Multidrug Resistance-Associated Proteins | 9 | 2024 | 105 | 1.250 |
Why?
|
| Enterobacteriaceae Infections | 7 | 2017 | 190 | 1.210 |
Why?
|
| Enterobacter cloacae | 3 | 2024 | 25 | 1.180 |
Why?
|
| Enterococcus | 6 | 2017 | 158 | 1.150 |
Why?
|
| Genes, Bacterial | 14 | 2018 | 1076 | 1.130 |
Why?
|
| Genetic Fitness | 2 | 2019 | 120 | 1.120 |
Why?
|
| Pseudomonas aeruginosa | 8 | 2024 | 1276 | 1.060 |
Why?
|
| Urinary Tract Infections | 9 | 2020 | 804 | 0.970 |
Why?
|
| Infection Control | 7 | 2022 | 984 | 0.960 |
Why?
|
| Phenazines | 1 | 2024 | 53 | 0.930 |
Why?
|
| Clostridium botulinum | 2 | 2014 | 21 | 0.900 |
Why?
|
| Botulism | 2 | 2014 | 21 | 0.900 |
Why?
|
| Acinetobacter baumannii | 3 | 2020 | 125 | 0.890 |
Why?
|
| Staphylococcal Skin Infections | 7 | 2014 | 78 | 0.840 |
Why?
|
| Acetyltransferases | 4 | 2009 | 230 | 0.840 |
Why?
|
| Equipment Contamination | 3 | 2019 | 183 | 0.830 |
Why?
|
| Acinetobacter Infections | 2 | 2020 | 74 | 0.820 |
Why?
|
| Bacteria | 14 | 2023 | 2212 | 0.820 |
Why?
|
| Bacteriological Techniques | 2 | 2014 | 277 | 0.790 |
Why?
|
| Botulinum Toxins | 2 | 2014 | 191 | 0.790 |
Why?
|
| Teichoic Acids | 2 | 2019 | 70 | 0.770 |
Why?
|
| Vibrio vulnificus | 1 | 2021 | 10 | 0.760 |
Why?
|
| Norfloxacin | 10 | 2010 | 24 | 0.710 |
Why?
|
| Escherichia coli Infections | 6 | 2020 | 518 | 0.690 |
Why?
|
| Epithelial Cells | 3 | 2017 | 3698 | 0.690 |
Why?
|
| Gram-Positive Bacterial Infections | 5 | 2014 | 340 | 0.690 |
Why?
|
| Polymerase Chain Reaction | 8 | 2015 | 6066 | 0.690 |
Why?
|
| Vancomycin Resistance | 5 | 2012 | 125 | 0.690 |
Why?
|
| Quinolines | 5 | 2011 | 769 | 0.690 |
Why?
|
| Vancomycin | 3 | 2017 | 504 | 0.680 |
Why?
|
| Gram-Negative Bacteria | 3 | 2019 | 276 | 0.680 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2019 | 347 | 0.670 |
Why?
|
| Congo Red | 1 | 2019 | 49 | 0.650 |
Why?
|
| Tunicamycin | 1 | 2019 | 108 | 0.650 |
Why?
|
| Pseudomonas Infections | 1 | 2024 | 622 | 0.650 |
Why?
|
| Genes, Regulator | 3 | 2011 | 373 | 0.640 |
Why?
|
| Aza Compounds | 3 | 2011 | 34 | 0.630 |
Why?
|
| DNA, Bacterial | 10 | 2018 | 1477 | 0.630 |
Why?
|
| Duodenoscopes | 1 | 2019 | 43 | 0.630 |
Why?
|
| Fosfomycin | 1 | 2018 | 26 | 0.610 |
Why?
|
| Methicillin | 2 | 2017 | 62 | 0.590 |
Why?
|
| Bacterial Infections | 10 | 2017 | 1390 | 0.590 |
Why?
|
| beta-Lactam Resistance | 3 | 2024 | 79 | 0.580 |
Why?
|
| Ornithine | 1 | 2017 | 79 | 0.570 |
Why?
|
| Citrates | 1 | 2017 | 132 | 0.560 |
Why?
|
| Organizational Policy | 2 | 2017 | 434 | 0.560 |
Why?
|
| Transcription, Genetic | 6 | 2017 | 7612 | 0.550 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2016 | 19 | 0.550 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2019 | 239 | 0.540 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 325 | 0.530 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 2017 | 566 | 0.520 |
Why?
|
| beta-Lactamases | 6 | 2024 | 308 | 0.510 |
Why?
|
| Phagosomes | 1 | 2017 | 194 | 0.500 |
Why?
|
| Mutation | 40 | 2021 | 30214 | 0.500 |
Why?
|
| Hospitals, General | 2 | 2017 | 804 | 0.500 |
Why?
|
| Molecular Sequence Data | 23 | 2014 | 17609 | 0.500 |
Why?
|
| Ofloxacin | 7 | 2002 | 66 | 0.490 |
Why?
|
| Catheter-Related Infections | 2 | 2015 | 279 | 0.490 |
Why?
|
| Vibrio | 2 | 2013 | 40 | 0.480 |
Why?
|
| Surgical Wound Infection | 10 | 2020 | 1547 | 0.480 |
Why?
|
| 4-Quinolones | 17 | 2003 | 25 | 0.470 |
Why?
|
| Quinine | 3 | 2021 | 51 | 0.470 |
Why?
|
| Promoter Regions, Genetic | 12 | 2020 | 5795 | 0.470 |
Why?
|
| Carbapenems | 3 | 2022 | 125 | 0.470 |
Why?
|
| Naphthyridines | 5 | 2005 | 184 | 0.450 |
Why?
|
| History of Medicine | 1 | 2014 | 42 | 0.450 |
Why?
|
| Chromosomes, Bacterial | 7 | 2011 | 281 | 0.450 |
Why?
|
| Hydroxyquinolines | 1 | 2013 | 17 | 0.440 |
Why?
|
| Protein Binding | 11 | 2019 | 9326 | 0.430 |
Why?
|
| Imidazoles | 1 | 2019 | 1168 | 0.420 |
Why?
|
| R Factors | 2 | 2017 | 35 | 0.410 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 1466 | 0.400 |
Why?
|
| Professional Competence | 1 | 2015 | 429 | 0.390 |
Why?
|
| Citrobacter | 1 | 2011 | 4 | 0.390 |
Why?
|
| Quorum Sensing | 1 | 2013 | 137 | 0.390 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2011 | 4570 | 0.390 |
Why?
|
| Oxacillin | 2 | 2024 | 41 | 0.380 |
Why?
|
| Base Sequence | 13 | 2020 | 12415 | 0.380 |
Why?
|
| Shewanella | 1 | 2010 | 12 | 0.370 |
Why?
|
| Coumarins | 5 | 1998 | 119 | 0.360 |
Why?
|
| Trans-Activators | 3 | 2017 | 2856 | 0.360 |
Why?
|
| Patient Transfer | 2 | 2017 | 789 | 0.360 |
Why?
|
| Babesiosis | 1 | 2012 | 92 | 0.360 |
Why?
|
| Nasal Mucosa | 1 | 2014 | 416 | 0.350 |
Why?
|
| Carrier State | 1 | 2014 | 530 | 0.350 |
Why?
|
| Nafcillin | 2 | 2024 | 23 | 0.340 |
Why?
|
| Genetic Complementation Test | 4 | 2017 | 556 | 0.340 |
Why?
|
| Rabies virus | 1 | 2009 | 37 | 0.330 |
Why?
|
| Oxidoreductases | 1 | 2012 | 409 | 0.330 |
Why?
|
| Salmonella enterica | 2 | 2006 | 75 | 0.330 |
Why?
|
| Ceftazidime | 2 | 2024 | 57 | 0.330 |
Why?
|
| Rabies | 1 | 2009 | 56 | 0.330 |
Why?
|
| DNA-Binding Proteins | 5 | 2020 | 9613 | 0.320 |
Why?
|
| Virulence Factors | 1 | 2012 | 498 | 0.320 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 1168 | 0.320 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2020 | 641 | 0.310 |
Why?
|
| Novobiocin | 6 | 2015 | 33 | 0.310 |
Why?
|
| Humans | 114 | 2024 | 766812 | 0.310 |
Why?
|
| Methicillin Resistance | 6 | 2015 | 198 | 0.310 |
Why?
|
| Gene Expression | 2 | 2013 | 7585 | 0.310 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 3738 | 0.300 |
Why?
|
| Repressor Proteins | 4 | 2015 | 2979 | 0.300 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 614 | 0.300 |
Why?
|
| Outpatients | 3 | 2020 | 1596 | 0.300 |
Why?
|
| Nocardia Infections | 2 | 1998 | 19 | 0.290 |
Why?
|
| Biofilms | 3 | 2024 | 641 | 0.290 |
Why?
|
| Iron | 4 | 2020 | 1812 | 0.290 |
Why?
|
| Cloning, Molecular | 7 | 2015 | 4168 | 0.290 |
Why?
|
| Conjugation, Genetic | 7 | 2009 | 116 | 0.290 |
Why?
|
| Skin Diseases, Infectious | 3 | 2021 | 75 | 0.290 |
Why?
|
| Structure-Activity Relationship | 9 | 2021 | 3053 | 0.290 |
Why?
|
| Sentinel Surveillance | 3 | 2018 | 292 | 0.280 |
Why?
|
| Enterococcus faecium | 2 | 1998 | 101 | 0.270 |
Why?
|
| Cold Temperature | 1 | 2010 | 793 | 0.270 |
Why?
|
| Transcription Factors | 4 | 2020 | 12159 | 0.270 |
Why?
|
| Electrophoretic Mobility Shift Assay | 3 | 2014 | 294 | 0.260 |
Why?
|
| Stress, Physiological | 1 | 2014 | 1407 | 0.260 |
Why?
|
| Klebsiella Infections | 2 | 2005 | 146 | 0.260 |
Why?
|
| Central Nervous System | 3 | 2009 | 1345 | 0.260 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 2 | 2008 | 109 | 0.260 |
Why?
|
| Communicable Diseases | 1 | 2014 | 872 | 0.260 |
Why?
|
| Models, Theoretical | 1 | 2017 | 3563 | 0.240 |
Why?
|
| DNA Primers | 3 | 2021 | 2826 | 0.240 |
Why?
|
| Microbial Viability | 2 | 2017 | 236 | 0.240 |
Why?
|
| Periplasm | 1 | 2024 | 43 | 0.240 |
Why?
|
| Amino Acid Sequence | 13 | 2011 | 13411 | 0.240 |
Why?
|
| Patient Admission | 1 | 2012 | 1364 | 0.240 |
Why?
|
| Colectomy | 2 | 2020 | 696 | 0.240 |
Why?
|
| Boston | 9 | 2020 | 9346 | 0.230 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2012 | 1965 | 0.230 |
Why?
|
| Community-Acquired Infections | 4 | 2020 | 470 | 0.230 |
Why?
|
| DNA Transposable Elements | 3 | 2017 | 764 | 0.230 |
Why?
|
| Enzymes | 1 | 2005 | 254 | 0.230 |
Why?
|
| Pyocyanine | 1 | 2024 | 20 | 0.230 |
Why?
|
| Protein Kinases | 2 | 2022 | 1610 | 0.230 |
Why?
|
| Meningitis, Viral | 1 | 2004 | 49 | 0.230 |
Why?
|
| Meningitis, Aseptic | 1 | 2004 | 59 | 0.230 |
Why?
|
| Disease Outbreaks | 5 | 2022 | 1761 | 0.220 |
Why?
|
| Soft Tissue Infections | 3 | 2012 | 166 | 0.220 |
Why?
|
| Pyrrolidines | 1 | 2005 | 339 | 0.220 |
Why?
|
| Cellulitis | 3 | 2016 | 206 | 0.220 |
Why?
|
| Sequence Analysis, DNA | 6 | 2020 | 4780 | 0.220 |
Why?
|
| Vibrio cholerae | 1 | 2009 | 793 | 0.220 |
Why?
|
| Mice | 17 | 2024 | 81898 | 0.210 |
Why?
|
| Biological Transport, Active | 4 | 2006 | 323 | 0.210 |
Why?
|
| DNA Topoisomerases | 1 | 2003 | 4 | 0.210 |
Why?
|
| Population Surveillance | 5 | 2012 | 2594 | 0.210 |
Why?
|
| Herpesvirus 2, Human | 1 | 2004 | 191 | 0.210 |
Why?
|
| Ambulatory Care | 1 | 2014 | 2779 | 0.210 |
Why?
|
| Ceftriaxone | 1 | 2023 | 176 | 0.210 |
Why?
|
| Immunologic Factors | 1 | 2012 | 1594 | 0.200 |
Why?
|
| Chloramphenicol | 2 | 2023 | 67 | 0.200 |
Why?
|
| Phylogeny | 3 | 2020 | 2840 | 0.200 |
Why?
|
| Animals | 32 | 2024 | 168939 | 0.200 |
Why?
|
| Proteolipids | 1 | 2002 | 109 | 0.200 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2002 | 72 | 0.190 |
Why?
|
| Gloves, Protective | 1 | 2001 | 23 | 0.190 |
Why?
|
| Alleles | 8 | 2011 | 6896 | 0.190 |
Why?
|
| Mupirocin | 1 | 2021 | 55 | 0.190 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 541 | 0.190 |
Why?
|
| Korea | 2 | 2013 | 97 | 0.190 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 1999 | 70 | 0.190 |
Why?
|
| Gram-Positive Bacteria | 1 | 2002 | 180 | 0.190 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2007 | 820 | 0.190 |
Why?
|
| Stethoscopes | 1 | 2001 | 30 | 0.190 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2022 | 148 | 0.190 |
Why?
|
| Protective Clothing | 1 | 2001 | 103 | 0.180 |
Why?
|
| Anthozoa | 1 | 2021 | 65 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 2 | 2011 | 1804 | 0.180 |
Why?
|
| Sequence Analysis | 1 | 2021 | 240 | 0.180 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2011 | 1417 | 0.180 |
Why?
|
| Herpes Simplex | 1 | 2004 | 470 | 0.180 |
Why?
|
| Rec A Recombinases | 2 | 2015 | 50 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 4349 | 0.180 |
Why?
|
| Chlorhexidine | 1 | 2021 | 159 | 0.180 |
Why?
|
| Hospitals | 6 | 2019 | 3885 | 0.170 |
Why?
|
| Blood-Brain Barrier | 1 | 2007 | 1028 | 0.170 |
Why?
|
| Bacteriolysis | 1 | 2000 | 51 | 0.170 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2014 | 2478 | 0.170 |
Why?
|
| Antibodies, Viral | 2 | 2009 | 3213 | 0.170 |
Why?
|
| Genome, Viral | 2 | 2021 | 674 | 0.170 |
Why?
|
| Aspergillus fumigatus | 1 | 2021 | 158 | 0.170 |
Why?
|
| Oxygen | 1 | 2012 | 4252 | 0.170 |
Why?
|
| Bacterial Adhesion | 2 | 2003 | 306 | 0.170 |
Why?
|
| Drug Resistance, Multiple | 2 | 2002 | 256 | 0.170 |
Why?
|
| Patient Isolation | 1 | 2020 | 101 | 0.170 |
Why?
|
| Operon | 1 | 2020 | 371 | 0.170 |
Why?
|
| Ultraviolet Therapy | 1 | 2020 | 82 | 0.170 |
Why?
|
| 5' Untranslated Regions | 1 | 2001 | 255 | 0.170 |
Why?
|
| Mitomycin | 2 | 2011 | 261 | 0.160 |
Why?
|
| Burn Units | 1 | 2020 | 143 | 0.160 |
Why?
|
| Mycoses | 2 | 2017 | 389 | 0.160 |
Why?
|
| Porphyrins | 1 | 2021 | 352 | 0.160 |
Why?
|
| Integration Host Factors | 1 | 2018 | 12 | 0.160 |
Why?
|
| Cephalosporins | 2 | 2021 | 200 | 0.160 |
Why?
|
| Colistin | 1 | 2019 | 46 | 0.160 |
Why?
|
| Spinal Cord | 1 | 2007 | 1811 | 0.160 |
Why?
|
| Lac Operon | 1 | 2018 | 237 | 0.150 |
Why?
|
| Disease Models, Animal | 8 | 2018 | 18329 | 0.150 |
Why?
|
| Bacterial Outer Membrane Proteins | 3 | 1992 | 404 | 0.150 |
Why?
|
| Coagulase | 1 | 1998 | 53 | 0.150 |
Why?
|
| Liposomes | 1 | 2002 | 787 | 0.150 |
Why?
|
| Potassium | 1 | 2022 | 1314 | 0.150 |
Why?
|
| Massachusetts | 7 | 2022 | 8890 | 0.150 |
Why?
|
| Bacteremia | 2 | 2010 | 987 | 0.150 |
Why?
|
| Staphylococcus | 1 | 1998 | 145 | 0.140 |
Why?
|
| International Classification of Diseases | 3 | 2012 | 935 | 0.140 |
Why?
|
| Bacterial Load | 1 | 2018 | 155 | 0.140 |
Why?
|
| Indoles | 2 | 2002 | 1834 | 0.140 |
Why?
|
| Erythromycin | 1 | 2017 | 114 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2011 | 1389 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 4 | 2014 | 3759 | 0.140 |
Why?
|
| Mass Screening | 1 | 2013 | 5454 | 0.140 |
Why?
|
| Siderophores | 1 | 2017 | 61 | 0.140 |
Why?
|
| Diverticulitis | 1 | 2019 | 187 | 0.140 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2018 | 135 | 0.140 |
Why?
|
| Sodium | 1 | 2022 | 1594 | 0.140 |
Why?
|
| Skin | 5 | 2020 | 4499 | 0.140 |
Why?
|
| Cefazolin | 2 | 2014 | 94 | 0.140 |
Why?
|
| Respiratory Tract Infections | 4 | 2000 | 1008 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2006 | 12795 | 0.130 |
Why?
|
| Burkholderia cepacia | 1 | 1996 | 22 | 0.130 |
Why?
|
| Zinc | 1 | 2020 | 675 | 0.130 |
Why?
|
| Male | 39 | 2020 | 364154 | 0.130 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 4787 | 0.130 |
Why?
|
| Burkholderia Infections | 1 | 1996 | 41 | 0.130 |
Why?
|
| Preoperative Care | 2 | 2020 | 2253 | 0.130 |
Why?
|
| Ventilators, Mechanical | 1 | 2018 | 292 | 0.130 |
Why?
|
| Genetic Vectors | 1 | 2005 | 3401 | 0.130 |
Why?
|
| Drug Hypersensitivity | 2 | 2015 | 903 | 0.130 |
Why?
|
| Universal Precautions | 1 | 2015 | 34 | 0.130 |
Why?
|
| United States | 16 | 2022 | 72945 | 0.130 |
Why?
|
| Chloroquine | 1 | 2017 | 276 | 0.120 |
Why?
|
| Virulence | 1 | 2019 | 1294 | 0.120 |
Why?
|
| Drug Prescriptions | 2 | 2015 | 1663 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2015 | 5943 | 0.120 |
Why?
|
| Antitoxins | 1 | 2015 | 75 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 560 | 0.120 |
Why?
|
| Fungi | 1 | 2017 | 346 | 0.120 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 804 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 1677 | 0.120 |
Why?
|
| Isopropyl Thiogalactoside | 1 | 2014 | 11 | 0.120 |
Why?
|
| Cytotoxins | 1 | 2015 | 154 | 0.120 |
Why?
|
| Phototherapy | 1 | 2017 | 368 | 0.120 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 59548 | 0.120 |
Why?
|
| Pyrroles | 1 | 2000 | 1121 | 0.120 |
Why?
|
| Bambermycins | 1 | 2014 | 11 | 0.110 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2015 | 463 | 0.110 |
Why?
|
| Transformation, Bacterial | 3 | 2017 | 79 | 0.110 |
Why?
|
| Hospitals, Teaching | 2 | 2015 | 1156 | 0.110 |
Why?
|
| DNA, Superhelical | 1 | 2014 | 51 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2019 | 2215 | 0.110 |
Why?
|
| Female | 39 | 2020 | 396532 | 0.110 |
Why?
|
| Workplace | 1 | 2020 | 873 | 0.110 |
Why?
|
| Burns | 2 | 2023 | 1902 | 0.110 |
Why?
|
| Disinfection | 1 | 2016 | 207 | 0.110 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2005 | 1729 | 0.110 |
Why?
|
| Culture Media | 3 | 2012 | 893 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2006 | 2746 | 0.110 |
Why?
|
| Peptidoglycan Glycosyltransferase | 1 | 2013 | 65 | 0.110 |
Why?
|
| Cephalexin | 1 | 2013 | 37 | 0.110 |
Why?
|
| Polyamines | 1 | 2013 | 132 | 0.110 |
Why?
|
| Intensive Care Units | 4 | 2020 | 3799 | 0.110 |
Why?
|
| Sequence Alignment | 4 | 2017 | 2177 | 0.100 |
Why?
|
| Bioterrorism | 1 | 2013 | 144 | 0.100 |
Why?
|
| Middle Aged | 27 | 2020 | 223267 | 0.100 |
Why?
|
| Enzyme Induction | 1 | 2013 | 455 | 0.100 |
Why?
|
| Allergy and Immunology | 1 | 2014 | 170 | 0.100 |
Why?
|
| Actinobacteria | 1 | 2013 | 62 | 0.100 |
Why?
|
| Genital Diseases, Male | 2 | 1989 | 84 | 0.100 |
Why?
|
| Cell Wall | 3 | 2017 | 419 | 0.100 |
Why?
|
| Aged | 25 | 2020 | 171344 | 0.100 |
Why?
|
| Piperazines | 2 | 2000 | 2547 | 0.100 |
Why?
|
| Food Microbiology | 1 | 2012 | 73 | 0.100 |
Why?
|
| Animal Feed | 1 | 2012 | 105 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 3 | 2020 | 6225 | 0.100 |
Why?
|
| Citrobacter freundii | 1 | 2011 | 1 | 0.100 |
Why?
|
| Penicillins | 1 | 2015 | 404 | 0.100 |
Why?
|
| Amino Acid Substitution | 2 | 2014 | 1742 | 0.100 |
Why?
|
| Nose | 1 | 2015 | 522 | 0.100 |
Why?
|
| Oligosaccharides | 1 | 2013 | 406 | 0.090 |
Why?
|
| Genital Diseases, Female | 2 | 1989 | 192 | 0.090 |
Why?
|
| Prevalence | 2 | 2020 | 15835 | 0.090 |
Why?
|
| Mycobacterium | 1 | 2013 | 252 | 0.090 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2012 | 134 | 0.090 |
Why?
|
| Education | 1 | 2014 | 531 | 0.090 |
Why?
|
| Mandatory Reporting | 1 | 2012 | 123 | 0.090 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 857 | 0.090 |
Why?
|
| Sepsis | 2 | 2019 | 2604 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2011 | 5022 | 0.090 |
Why?
|
| Coronary Artery Bypass | 3 | 2011 | 2189 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 2 | 2009 | 497 | 0.090 |
Why?
|
| Rabies Vaccines | 1 | 2009 | 29 | 0.080 |
Why?
|
| Nalidixic Acid | 3 | 2000 | 19 | 0.080 |
Why?
|
| Medical Records | 2 | 2012 | 1408 | 0.080 |
Why?
|
| Enterococcus faecalis | 1 | 2011 | 244 | 0.080 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2009 | 149 | 0.080 |
Why?
|
| Public Health Administration | 1 | 2012 | 242 | 0.080 |
Why?
|
| Pyridones | 1 | 1995 | 818 | 0.080 |
Why?
|
| Inappropriate Prescribing | 1 | 2012 | 212 | 0.080 |
Why?
|
| Kinetics | 4 | 2008 | 6288 | 0.080 |
Why?
|
| Proteus Infections | 1 | 2009 | 10 | 0.080 |
Why?
|
| Quinolizines | 2 | 2005 | 20 | 0.080 |
Why?
|
| Endopeptidases | 2 | 2005 | 762 | 0.080 |
Why?
|
| Proteus mirabilis | 1 | 2009 | 24 | 0.080 |
Why?
|
| Prostatitis | 1 | 1989 | 102 | 0.080 |
Why?
|
| Drainage | 3 | 2005 | 1182 | 0.080 |
Why?
|
| Risk Factors | 9 | 2015 | 74889 | 0.080 |
Why?
|
| Inpatients | 5 | 2019 | 2566 | 0.080 |
Why?
|
| Staphylococcus epidermidis | 3 | 2001 | 121 | 0.080 |
Why?
|
| Retrospective Studies | 18 | 2023 | 81657 | 0.080 |
Why?
|
| Trypanosoma cruzi | 2 | 1989 | 204 | 0.080 |
Why?
|
| DNA | 3 | 1993 | 7210 | 0.080 |
Why?
|
| Rifampin | 1 | 2011 | 350 | 0.080 |
Why?
|
| Pneumonia | 1 | 2020 | 2161 | 0.080 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2021 | 335 | 0.080 |
Why?
|
| Dermatitis | 2 | 2009 | 203 | 0.080 |
Why?
|
| Policy | 1 | 2012 | 512 | 0.080 |
Why?
|
| Light | 3 | 2021 | 1358 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2887 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 2 | 2001 | 663 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 1998 | 142 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2014 | 1574 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12064 | 0.070 |
Why?
|
| Mycoplasma Infections | 1 | 1988 | 120 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3667 | 0.070 |
Why?
|
| Binding Sites | 4 | 2017 | 6013 | 0.070 |
Why?
|
| Gluconates | 1 | 2007 | 31 | 0.070 |
Why?
|
| Genes, MDR | 1 | 2007 | 36 | 0.070 |
Why?
|
| Adult | 19 | 2020 | 223305 | 0.070 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2011 | 1044 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2010 | 319 | 0.070 |
Why?
|
| Child | 12 | 2024 | 80670 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 14653 | 0.070 |
Why?
|
| Acetylation | 2 | 2008 | 1055 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 9528 | 0.070 |
Why?
|
| Cohort Studies | 7 | 2020 | 41706 | 0.070 |
Why?
|
| Data Collection | 2 | 2012 | 3321 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2014 | 2764 | 0.070 |
Why?
|
| Sodium Chloride | 2 | 2000 | 580 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 2 | 2002 | 764 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3431 | 0.060 |
Why?
|
| Point Mutation | 3 | 2013 | 1592 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5330 | 0.060 |
Why?
|
| Serotyping | 1 | 2006 | 331 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2013 | 1806 | 0.060 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 2783 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1996 | 766 | 0.060 |
Why?
|
| Office Visits | 1 | 2009 | 593 | 0.060 |
Why?
|
| Tetracyclines | 1 | 2005 | 64 | 0.060 |
Why?
|
| Substrate Specificity | 2 | 2008 | 1750 | 0.060 |
Why?
|
| Permeability | 1 | 2007 | 721 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2012 | 2669 | 0.060 |
Why?
|
| Time Factors | 6 | 2012 | 40149 | 0.060 |
Why?
|
| Dinucleoside Phosphates | 1 | 2024 | 71 | 0.060 |
Why?
|
| Pasteurella Infections | 1 | 1984 | 8 | 0.060 |
Why?
|
| Drug Resistance | 2 | 2002 | 1592 | 0.060 |
Why?
|
| Prosthesis Implantation | 1 | 2009 | 594 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 2000 | 3723 | 0.060 |
Why?
|
| Chromatography, Affinity | 1 | 2005 | 524 | 0.060 |
Why?
|
| Temperature | 3 | 2003 | 2231 | 0.060 |
Why?
|
| Nitrogen | 1 | 2005 | 344 | 0.060 |
Why?
|
| Chromosome Mapping | 4 | 1996 | 4618 | 0.060 |
Why?
|
| Second Messenger Systems | 1 | 2024 | 203 | 0.060 |
Why?
|
| RNA, Bacterial | 1 | 2006 | 393 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2001 | 3624 | 0.060 |
Why?
|
| Molecular Weight | 2 | 2000 | 2168 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2024 | 205 | 0.060 |
Why?
|
| Hydroxyl Radical | 1 | 2023 | 81 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 10745 | 0.050 |
Why?
|
| Peptidoglycan | 2 | 2017 | 246 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1673 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2005 | 607 | 0.050 |
Why?
|
| Molecular Structure | 2 | 2017 | 1882 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 15425 | 0.050 |
Why?
|
| Medicare | 2 | 2011 | 6813 | 0.050 |
Why?
|
| Genetic Techniques | 1 | 2005 | 427 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2022 | 54872 | 0.050 |
Why?
|
| Cell Line | 1 | 2017 | 15564 | 0.050 |
Why?
|
| Monkeypox virus | 1 | 2022 | 43 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2014 | 3139 | 0.050 |
Why?
|
| Skin Tests | 2 | 2015 | 630 | 0.050 |
Why?
|
| Wound Infection | 2 | 2016 | 244 | 0.050 |
Why?
|
| Biological Availability | 3 | 1998 | 387 | 0.050 |
Why?
|
| Urban Population | 1 | 2010 | 2040 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5536 | 0.050 |
Why?
|
| Thorax | 1 | 2005 | 555 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2015 | 8728 | 0.050 |
Why?
|
| Anticoagulants | 1 | 1998 | 4854 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2021 | 9661 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 1550 | 0.050 |
Why?
|
| Genetic Linkage | 2 | 2001 | 2342 | 0.050 |
Why?
|
| Antigen-Antibody Complex | 1 | 1983 | 512 | 0.050 |
Why?
|
| Spores, Fungal | 1 | 2021 | 89 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 1622 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 2198 | 0.050 |
Why?
|
| Organoids | 1 | 1987 | 740 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2011 | 22248 | 0.050 |
Why?
|
| Detergents | 1 | 2021 | 235 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 7430 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2007 | 1188 | 0.040 |
Why?
|
| DNA, Viral | 2 | 2004 | 2201 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5890 | 0.040 |
Why?
|
| Age Distribution | 1 | 2006 | 2869 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7870 | 0.040 |
Why?
|
| Plankton | 1 | 2020 | 21 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 6965 | 0.040 |
Why?
|
| Contact Tracing | 1 | 2022 | 274 | 0.040 |
Why?
|
| Fibronectins | 1 | 2003 | 722 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2006 | 1181 | 0.040 |
Why?
|
| Potassium Chloride | 1 | 2000 | 228 | 0.040 |
Why?
|
| Sterilization | 1 | 2001 | 132 | 0.040 |
Why?
|
| Catheterization | 1 | 2005 | 1429 | 0.040 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2001 | 133 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 9244 | 0.040 |
Why?
|
| Phenotype | 3 | 2005 | 16722 | 0.040 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2000 | 31 | 0.040 |
Why?
|
| Endocarditis, Bacterial | 1 | 1983 | 436 | 0.040 |
Why?
|
| Klebsiella | 1 | 1999 | 49 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 26309 | 0.040 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2000 | 65 | 0.040 |
Why?
|
| Abdomen | 1 | 2005 | 1137 | 0.040 |
Why?
|
| Molecular Epidemiology | 2 | 2013 | 473 | 0.040 |
Why?
|
| Metals, Heavy | 1 | 2000 | 149 | 0.040 |
Why?
|
| Recurrence | 2 | 2004 | 8507 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2010 | 8310 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 834 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 17089 | 0.040 |
Why?
|
| Infection Control Practitioners | 1 | 2018 | 12 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 1027 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2007 | 3157 | 0.040 |
Why?
|
| Treatment Outcome | 6 | 2020 | 65286 | 0.040 |
Why?
|
| Magnesium | 2 | 1994 | 815 | 0.040 |
Why?
|
| Aminocoumarins | 3 | 1989 | 9 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2013 | 3459 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 618 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 1431 | 0.040 |
Why?
|
| Drug Interactions | 2 | 1993 | 1419 | 0.040 |
Why?
|
| Adolescent | 11 | 2019 | 88902 | 0.030 |
Why?
|
| China | 1 | 2003 | 2386 | 0.030 |
Why?
|
| Species Specificity | 1 | 2001 | 2413 | 0.030 |
Why?
|
| Algorithms | 4 | 2020 | 14073 | 0.030 |
Why?
|
| Models, Molecular | 3 | 2013 | 5388 | 0.030 |
Why?
|
| Clindamycin | 1 | 1997 | 138 | 0.030 |
Why?
|
| Workflow | 1 | 2021 | 859 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2017 | 6613 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2002 | 862 | 0.030 |
Why?
|
| Anesthesiology | 1 | 2007 | 1137 | 0.030 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1999 | 366 | 0.030 |
Why?
|
| Lasers | 1 | 2001 | 951 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2000 | 877 | 0.030 |
Why?
|
| Child, Preschool | 7 | 2013 | 42577 | 0.030 |
Why?
|
| Infant | 5 | 2009 | 36459 | 0.030 |
Why?
|
| Porins | 1 | 2015 | 78 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 2144 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2001 | 956 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1996 | 138 | 0.030 |
Why?
|
| Endophthalmitis | 1 | 1998 | 263 | 0.030 |
Why?
|
| Eye Infections, Bacterial | 1 | 1998 | 239 | 0.030 |
Why?
|
| General Surgery | 1 | 2007 | 1720 | 0.030 |
Why?
|
| Logistic Models | 3 | 2019 | 13276 | 0.030 |
Why?
|
| Young Adult | 5 | 2019 | 59939 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1983 | 1464 | 0.030 |
Why?
|
| Reserpine | 1 | 1994 | 63 | 0.030 |
Why?
|
| Safety Management | 1 | 2020 | 765 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 3 | 1999 | 899 | 0.030 |
Why?
|
| Mitochondria | 1 | 1987 | 3678 | 0.030 |
Why?
|
| Occupational Health | 1 | 2020 | 812 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 1927 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2000 | 668 | 0.030 |
Why?
|
| Tobramycin | 1 | 1993 | 65 | 0.030 |
Why?
|
| Verapamil | 1 | 1994 | 242 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2003 | 3642 | 0.030 |
Why?
|
| Rodentia | 1 | 1995 | 262 | 0.030 |
Why?
|
| Adhesins, Escherichia coli | 1 | 2013 | 7 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2021 | 2867 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 1670 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2017 | 840 | 0.030 |
Why?
|
| Reference Values | 1 | 2020 | 4914 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2715 | 0.030 |
Why?
|
| Sex Factors | 1 | 2007 | 10619 | 0.030 |
Why?
|
| Glucose | 1 | 2024 | 4340 | 0.030 |
Why?
|
| Terminology as Topic | 2 | 2012 | 1540 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2013 | 102 | 0.030 |
Why?
|
| Length of Stay | 2 | 2016 | 6491 | 0.030 |
Why?
|
| Arthritis, Infectious | 2 | 1988 | 347 | 0.030 |
Why?
|
| Fimbriae Proteins | 1 | 2013 | 133 | 0.030 |
Why?
|
| Breast Implants | 1 | 1996 | 414 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1331 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2014 | 826 | 0.020 |
Why?
|
| Professional Practice | 1 | 2014 | 314 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2017 | 796 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1991 | 205 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2007 | 14473 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2017 | 3587 | 0.020 |
Why?
|
| Health Care Surveys | 2 | 2009 | 2425 | 0.020 |
Why?
|
| Disease Notification | 1 | 2011 | 95 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10451 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 2012 | 141 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2012 | 190 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 22351 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2015 | 871 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 774 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1991 | 848 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2011 | 166 | 0.020 |
Why?
|
| Colonic Diseases | 1 | 2012 | 204 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 20146 | 0.020 |
Why?
|
| Hospitalization | 2 | 2020 | 10816 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 39312 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2016 | 2659 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2020 | 2694 | 0.020 |
Why?
|
| Dogs | 2 | 2005 | 3834 | 0.020 |
Why?
|
| Patient Discharge | 3 | 2011 | 3466 | 0.020 |
Why?
|
| Biological Transport | 1 | 1994 | 2083 | 0.020 |
Why?
|
| Spheroplasts | 1 | 1989 | 6 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 10263 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 6306 | 0.020 |
Why?
|
| Hospital Administration | 1 | 2012 | 351 | 0.020 |
Why?
|
| Rabbits | 4 | 1998 | 4752 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 29959 | 0.020 |
Why?
|
| Stereoisomerism | 2 | 2005 | 612 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 1211 | 0.020 |
Why?
|
| Mycoplasma | 1 | 1988 | 146 | 0.020 |
Why?
|
| Administration, Oral | 2 | 1998 | 4019 | 0.020 |
Why?
|
| Rhodamine 123 | 1 | 1987 | 37 | 0.020 |
Why?
|
| Nifurtimox | 1 | 1987 | 14 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2008 | 161 | 0.020 |
Why?
|
| Rhodamines | 1 | 1987 | 179 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 2513 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2012 | 863 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 1642 | 0.020 |
Why?
|
| Genotype | 1 | 2001 | 13036 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1991 | 2275 | 0.020 |
Why?
|
| Incidence | 2 | 2020 | 21527 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 1494 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 3384 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2921 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10101 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1998 | 2416 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 1989 | 899 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 2210 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 1394 | 0.020 |
Why?
|
| Coliphages | 1 | 1985 | 121 | 0.020 |
Why?
|
| Linear Models | 1 | 2016 | 5873 | 0.020 |
Why?
|
| Colony Count, Microbial | 2 | 1998 | 326 | 0.020 |
Why?
|
| Oxazines | 1 | 1987 | 358 | 0.020 |
Why?
|
| Muscles | 1 | 1990 | 1576 | 0.020 |
Why?
|
| Pasteurella | 1 | 1984 | 6 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1996 | 2727 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2019 | 24299 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2019 | 3850 | 0.010 |
Why?
|
| Half-Life | 1 | 2005 | 648 | 0.010 |
Why?
|
| ROC Curve | 1 | 2012 | 3621 | 0.010 |
Why?
|
| F Factor | 1 | 1983 | 12 | 0.010 |
Why?
|
| Concurrent Review | 1 | 2003 | 13 | 0.010 |
Why?
|
| Software | 1 | 2018 | 4464 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2012 | 1161 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2005 | 329 | 0.010 |
Why?
|
| Models, Biological | 2 | 2017 | 9464 | 0.010 |
Why?
|
| Self Report | 1 | 2015 | 3771 | 0.010 |
Why?
|
| Bites and Stings | 1 | 1984 | 94 | 0.010 |
Why?
|
| Prodrugs | 1 | 2005 | 274 | 0.010 |
Why?
|
| Zoonoses | 1 | 1984 | 180 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 1377 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1987 | 1075 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1998 | 4278 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2011 | 1506 | 0.010 |
Why?
|
| Cats | 1 | 1984 | 972 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1989 | 1441 | 0.010 |
Why?
|
| Genes | 1 | 1986 | 1824 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2002 | 108 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2005 | 1887 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 1639 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2008 | 1756 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1985 | 1384 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2018 | 4880 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2008 | 3948 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 2228 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1987 | 2629 | 0.010 |
Why?
|
| Apoptosis | 1 | 2016 | 9514 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1990 | 2559 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1988 | 1552 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7869 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2013 | 12430 | 0.010 |
Why?
|
| Lung | 1 | 1997 | 10068 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1989 | 2903 | 0.010 |
Why?
|
| Anterior Eye Segment | 1 | 1998 | 144 | 0.010 |
Why?
|
| Drug Design | 1 | 2002 | 1043 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2000 | 23618 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2009 | 26387 | 0.010 |
Why?
|
| DNA Replication | 1 | 1983 | 1426 | 0.010 |
Why?
|
| Vitreous Body | 1 | 1998 | 401 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2004 | 1418 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1999 | 1525 | 0.010 |
Why?
|
| Gene Dosage | 1 | 1999 | 1211 | 0.010 |
Why?
|
| Mammaplasty | 1 | 2004 | 1268 | 0.010 |
Why?
|
| Methylmethacrylates | 1 | 1993 | 66 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 2394 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 1993 | 152 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 2936 | 0.010 |
Why?
|
| Ilium | 1 | 1993 | 155 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 18397 | 0.010 |
Why?
|
| Methyl Methanesulfonate | 1 | 1989 | 28 | 0.010 |
Why?
|
| Nucleic Acid Precursors | 1 | 1989 | 16 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1993 | 702 | 0.000 |
Why?
|
| Rats | 1 | 2005 | 23717 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8540 | 0.000 |
Why?
|
| RNA Precursors | 1 | 1989 | 196 | 0.000 |
Why?
|
| Retina | 1 | 1998 | 2660 | 0.000 |
Why?
|
| Myositis | 1 | 1990 | 268 | 0.000 |
Why?
|
| Surgical Flaps | 1 | 1993 | 1680 | 0.000 |
Why?
|
| Protein Precursors | 1 | 1989 | 1134 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1990 | 2606 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 2551 | 0.000 |
Why?
|